Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCKET-ASTRO: Rocatinlimab in adolescents with moderate to severe atopic dermatitis
CTR20232032Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rocatinlimab in atopic dermatitis (AD), sponsored by Amgen. Started Oct 2023; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20232032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232032.